BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33676955)

  • 1. Therapeutic Consequences of Omitting a Pelvic Lymph Node Dissection at Radical Prostatectomy when Grade and/or Stage Increase.
    Altok M; Chapin BF; Matin SF; Achim MF; Gregg JR; Davis JW
    Urology; 2021 Sep; 155():144-151. PubMed ID: 33676955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgeon-led prostate cancer lymph node staging: pathological outcomes stratified by robot-assisted dissection templates and patient selection.
    Altok M; Babaian K; Achim MF; Achim GC; Troncoso P; Matin SF; Chapin BF; Davis JW
    BJU Int; 2018 Jul; 122(1):66-75. PubMed ID: 29446205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A critical assessment of the value of lymph node dissection at radical prostatectomy: A population-based study.
    Abdollah F; Schmitges J; Sun M; Tian Z; Briganti A; Shariat SF; Perrotte P; Montorsi F; Karakiewicz PI
    Prostate; 2011 Oct; 71(14):1587-94. PubMed ID: 21480307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer.
    Schiavina R; Manferrari F; Garofalo M; Bertaccini A; Vagnoni V; Guidi M; Borghesi M; Baccos A; Morselli-Labate AM; Concetti S; Martorana G
    BJU Int; 2011 Oct; 108(8):1262-8. PubMed ID: 21446934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Pelvic Lymph Node Dissection During Radical Prostatectomy in Patients With Gleason 6 Intermediate-risk Prostate Cancer.
    Mandel P; Kriegmair MC; Veleva V; Salomon G; Graefen M; Huland H; Tilki D
    Urology; 2016 Jul; 93():141-6. PubMed ID: 26968487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.
    Bhatta-Dhar N; Reuther AM; Zippe C; Klein EA
    Urology; 2004 Mar; 63(3):528-31. PubMed ID: 15028451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small-volume lymph node involvement and biochemical recurrence after robot-assisted radical prostatectomy with extended lymph node dissection in prostate cancer.
    Morizane S; Honda M; Shimizu R; Teraoka S; Nishikawa R; Tsounapi P; Kimura Y; Iwamoto H; Hikita K; Takenaka A
    Int J Clin Oncol; 2020 Jul; 25(7):1398-1404. PubMed ID: 32333202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No difference in biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients.
    Fergany A; Kupelian PA; Levin HS; Zippe CD; Reddy C; Klein EA
    Urology; 2000 Jul; 56(1):92-5. PubMed ID: 10869632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of the extent of lymph-node dissection on biochemical relapse after radical prostatectomy in node-negative patients.
    Schiavina R; Bertaccini A; Franceschelli A; Manferrari F; Vagnoni V; Borghesi M; Morselli-Labate AM; Martorana G
    Anticancer Res; 2010 Jun; 30(6):2297-302. PubMed ID: 20651383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era.
    Dorin RP; Lieskovsky G; Fairey AS; Cai J; Daneshmand S
    Urol Oncol; 2013 Nov; 31(8):1441-7. PubMed ID: 22516714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion >5%: a propensity score matching analysis from SEER database.
    Chen J; Wang Z; Zhao J; Zhu S; Sun G; Liu J; Zhang H; Zhang X; Shen P; Shi M; Zeng H
    Sci Rep; 2019 Nov; 9(1):17985. PubMed ID: 31784574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Prostate Cancer Upgrading and Upstaging on Biochemical Recurrence and Cancer-Specific Survival.
    Bakavičius A; Drevinskaitė M; Daniūnaitė K; Barisienė M; Jarmalaitė S; Jankevičius F
    Medicina (Kaunas); 2020 Feb; 56(2):. PubMed ID: 32033148
    [No Abstract]   [Full Text] [Related]  

  • 14. Lymph node yield during radical prostatectomy does not impact rate of biochemical recurrence in patients with seminal vesicle invasion and node-negative disease.
    Badani KK; Reddy BN; Moskowitz EJ; Paulucci DJ; Beksac AT; Martini A; Whalen MJ; Skarecky DW; Huynh LM; Ahlering TE
    Urol Oncol; 2018 Jun; 36(6):310.e1-310.e6. PubMed ID: 29625782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does pelvic lymph node dissection improve the biochemical relapse-free survival in low-risk prostate cancer patients treated by laparoscopic radical prostatectomy?
    Daimon T; Miyajima A; Maeda T; Hattori S; Yasumizu Y; Hasegawa M; Kosaka T; Kikuchi E; Nakagawa K; Oya M
    J Endourol; 2012 Sep; 26(9):1199-202. PubMed ID: 22524402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors associated with biochemical recurrence following radical prostatectomy for pathological T2 prostate cancer with negative surgical margins.
    Aoun F; Albisinni S; Henriet B; Tombal B; Van Velthoven R; Roumeguère T
    Scand J Urol; 2017 Feb; 51(1):20-26. PubMed ID: 27910728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indication for and extension of pelvic lymph node dissection during robot-assisted radical prostatectomy: an analysis of five European institutions.
    Suardi N; Larcher A; Haese A; Ficarra V; Govorov A; Buffi NM; Walz J; Rocco B; Borghesi M; Steuber T; Pini G; Briganti A; Mottrie AM; Guazzoni G; Montorsi F; Pushkar D; Van Der Poel H;
    Eur Urol; 2014 Oct; 66(4):635-43. PubMed ID: 24411992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer.
    Özsoy M; D'Andrea D; Moschini M; Foerster B; Abufaraj M; Mathieu R; Briganti A; Karakiewicz PI; Roupret M; Seitz C; Czech AK; Susani M; Shariat SF
    Urol Oncol; 2018 Apr; 36(4):158.e1-158.e6. PubMed ID: 29288003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical recurrence after robot-assisted extended pelvic lymphadenectomy for prostate cancer.
    Chenam A; Ruel N; Pal S; Barlog J; Lau C; Wilson T; Yuh B
    Can J Urol; 2018 Jun; 25(3):9340-9348. PubMed ID: 29900823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.